You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.
The test is based on the US Centers for Disease Control and Prevention's SARS-CoV-2 panel and detects two regions of the virus' nucleocapsid gene.
A team of researchers in Germany investigated gene expression in airway cells of SARS-CoV-2 patients, finding increased interaction between epithelial and immune cells.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
Investigators reported that methylation profiling could distinguish brain cancer subtypes and could detect kidney cancer with striking sensitivity in early experiments.
Both tests are authorized for use by any laboratory CLIA certified to perform high-complexity tests, according to the FDA.
The firm used the new loan to pay off an older $7.0 million loan and a $3.0 million promissory note held by Qiagen North American Holdings.
For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.
The firm said that its RAQ SARS-CoV-2 PCR Kit allows the replacement of full nucleic acid extraction with a simple heat treatment, decreasing sample processing time.
Both PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens and may only be performed by their developers.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
The SICILIAN algorithm, which uses statistical modeling to score candidate fusions in single-cell RNA sequencing data, is being used to map splice sites in individual tumor cells.
In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
The firm's SmartChip platform consists of a high-throughput liquid dispenser and a PCR instrument and can provide more than 5,000 reactions in one run.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
For the three months ended March 31, Rutherford, New Jersey-based Cancer Genetics posted revenues of $1.4 million versus $1.8 million in Q1 2019.
The two PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in respiratory samples including nasopharyngeal swabs and bronchoalveolar lavage specimens.
Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.
The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts.
The company is planning a fall launch aimed at the immuno-oncology market but has begun offering early access for SARS-CoV-2 research in the meantime.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.